1. Safety and preliminary clinical activity of NVL-520, a highly selective ROS1 inhibitor, in patients with advanced ROS1 fusion-positive solid tumors. (October 2022) Authors: Drilon, A.; Besse, B.; Camidge, D.R.; Ou, S.H.I.; Gadgeel, S.M.; Johnson, M.L.; Calles, A.; de Miguel, M.J.; Spira, A.I.; Felip, E.; Lopes, G.; van der Wekken, A.J.; Elamin, Y.Y.; Green, J.; Sun, Y.; Soglia, J.; Zhu, V.W.; Lin, J.J. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Phase Ib study of afatinib plus standard-dose cetuximab in patients with advanced solid tumours. (December 2016) Authors: Gazzah, A.; Boni, V.; Soria, J.C.; Calles, A.; Even, C.; Doger, B.; Mahjoubi, L.; Bahleda, R.; Ould-Kaci, M.; Esler, A.; Nazabadioko, S.; Calvo, E. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S139 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗